Details of the Drug

General Information of Drug (ID: DMHNYWP)

Drug Name

ISIS-GCGR

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Phase 2	[1]
Type-2 diabetes	5A11	Preclinical	[2]
------------------------------------------------------------------------------------

Drug Type

Antisense drug

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon receptor messenger RNA (GCGR mRNA)	TTLMJSC	GLR_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Diabetic complication

ICD Disease Classification

5A2Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Glucagon receptor messenger RNA (GCGR mRNA)	DTT	GCGR	7.24E-02	-0.52	-0.92

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01885260) Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).